Pyxis Oncology Stock Total Asset
| PYXS Stock | USD 1.89 0.01 0.53% |
Pyxis Oncology fundamentals help investors to digest information that contributes to Pyxis Oncology's financial success or failures. It also enables traders to predict the movement of Pyxis Stock. The fundamental analysis module provides a way to measure Pyxis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Pyxis Oncology stock.
| Last Reported | Projected for Next Year | ||
| Total Assets | 173.7 M | 152.9 M | |
| Intangibles To Total Assets | 0.13 | 0.11 |
Pyxis | Total Asset |
Pyxis Oncology Company Total Asset Analysis
Pyxis Oncology's Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Current Pyxis Oncology Total Asset | 173.73 M |
Most of Pyxis Oncology's fundamental indicators, such as Total Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pyxis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Pyxis Total Asset Driver Correlations
Understanding the fundamental principles of building solid financial models for Pyxis Oncology is extremely important. It helps to project a fair market value of Pyxis Stock properly, considering its historical fundamentals such as Total Asset. Since Pyxis Oncology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pyxis Oncology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pyxis Oncology's interrelated accounts and indicators.
Click cells to compare fundamentals
Pyxis Total Asset Historical Pattern
Today, most investors in Pyxis Oncology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Pyxis Oncology's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total asset growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Pyxis Oncology total asset as a starting point in their analysis.
Pyxis Oncology Total Asset |
| Timeline |
Total Asset is typically divided on the balance sheet on current asset and long-term asset. Long-term is the value of company property and other capital assets that are expected to be useable for more than one year. Long term assets are reported net of depreciation. On the other hand current assets are assets that are expected to be sold or converted to cash as part of normal business operation.
| Competition |
Pyxis Total Assets
Total Assets |
|
Based on the latest financial disclosure, Pyxis Oncology has a Total Asset of 173.73 M. This is 97.69% lower than that of the Biotechnology sector and 91.21% lower than that of the Health Care industry. The total asset for all United States stocks is 99.41% higher than that of the company.
Pyxis Total Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pyxis Oncology's direct or indirect competition against its Total Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pyxis Oncology could also be used in its relative valuation, which is a method of valuing Pyxis Oncology by comparing valuation metrics of similar companies.Pyxis Oncology is currently under evaluation in total asset category among its peers.
Pyxis Oncology Institutional Holders
Institutional Holdings refers to the ownership stake in Pyxis Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Pyxis Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pyxis Oncology's value.| Shares | Perceptive Advisors Llc | 2024-09-30 | 508.5 K | 683 Capital Management Llc | 2024-09-30 | 414.7 K | Northern Trust Corp | 2024-09-30 | 394 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 382.8 K | Hillhouse Capital Advisors, Ltd. | 2024-09-30 | 382.6 K | Decheng Capital Llc | 2024-06-30 | 326.8 K | Bank Of New York Mellon Corp | 2024-06-30 | 311.6 K | Boothbay Fund Management, Llc | 2024-09-30 | 283.6 K | Citadel Advisors Llc | 2024-09-30 | 276 K | Deep Track Capital, Lp | 2024-09-30 | 4.2 M | Laurion Capital Management Lp | 2024-09-30 | 3.6 M |
Pyxis Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (3.99) % | ||||
| Current Valuation | (11.29 M) | ||||
| Shares Outstanding | 59.47 M | ||||
| Shares Owned By Insiders | 24.54 % | ||||
| Shares Owned By Institutions | 54.50 % | ||||
| Number Of Shares Shorted | 5.86 M | ||||
| Price To Book | 0.74 X | ||||
| Price To Sales | 7.00 X | ||||
| EBITDA | (78.49 M) | ||||
| Net Income | (73.79 M) | ||||
| Cash And Equivalents | 223.36 M | ||||
| Cash Per Share | 7.48 X | ||||
| Total Debt | 21.33 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 15.19 X | ||||
| Book Value Per Share | 2.58 X | ||||
| Cash Flow From Operations | (70.71 M) | ||||
| Short Ratio | 10.78 X | ||||
| Earnings Per Share | (1.06) X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 10.67 | ||||
| Number Of Employees | 54 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 112.98 M | ||||
| Total Asset | 173.73 M | ||||
| Retained Earnings | (286.23 M) | ||||
| Working Capital | 98.84 M | ||||
| Net Asset | 173.73 M |
About Pyxis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pyxis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyxis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyxis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pyxis Stock Analysis
When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.